Plasma nitrate levels in deficit versus non-deficit forms of schizophrenia

Eiji Suzuki, MD, PhD; Toshio Nakaki, MD, PhD; Makoto Nakamura, MD; Hitoshi Miyaoka, MD, PhD

Objective: To determine whether nitric oxide production levels differ in patients with deficit and non-deficit forms of schizophrenia. Methods: We investigated plasma nitrate levels, an index of in vivo nitric oxide production, in patients with deficit syndrome (n = 11) and non-deficit syndrome (n = 14) and healthy controls (n = 12) with a combination of high-performance liquid chromatography and the Griess reaction. Results: There was no difference found in mean plasma nitrite levels, but plasma nitrate levels of patients with deficit syndrome were significantly lower than those with non-deficit syndrome (28.0 [SEM 2.5] µmol/L v. 44.2 [SEM 5.5] µmol/L, p < 0.05). Conclusions: A decline in nitric oxide production may be involved in primary negative symptoms in schizophrenia.

Objectif : Déterminer si les taux de production de monoxyde d’azote des patients aux prises avec une forme de schizophrénie s’accompagnant d’un déficit sont différents de ceux des patients souffrant de schizophrénie sans déficit. Méthodes : Nous avons examiné les concentrations plasmatiques de nitrate, indice de la production in vivo de monoxyde d’azote, chez des patients atteints d’un syndrome avec déficit (n = 11), chez des patients atteints d’un syndrome sans déficit (n = 14) et chez des témoins en bonne santé (n = 12), au moyen de la chromatographie en phase liquide à haut rendement et de la réaction de Griess. Résultats : On n’a pas observé de différence au chapitre des concentrations plasmatiques moyennes de nitrite, mais les concentrations plasmatiques de nitrate des patients aux prises avec un syndrome avec déficit étaient très inférieures à celles des patients atteints d’un syndrome sans déficit (28.0 [ETM 2.5] µmol/L c. 44.2 [ETM 5.5] µmol/L, p < 0.05). Conclusions : Une diminution de la production de monoxyde d’azote pourrait contribuer aux principaux symptômes négatifs de la schizophrénie.

Introduction

Since being identified as an endothelium-derived relaxing factor, nitric oxide (NO), which is biosynthesized in neurons as well as endothelium from L-arginine (L-Arg) by nitric oxide synthase (NOS), has been focused on as a physiologically active substance.1 At the cellular level, NO can modulate hormone secretion in the neuroendocrine system,2 as well as the release and reuptake of monoaminergic neurotransmitters,3–7 and is also

Correspondence to: Dr. Eiji Suzuki, Department of Psychiatry, Kitasato University School of Medicine, 2-1-1 Asamizodai, Sagamihara, Kanagawa, 228-8520, Japan; fax 81 42 765 3570; e-suzuki@kitasato-u.ac.jp

Medical subject headings: nitric oxide; nitric-oxide synthase; schizophrenia; signs and symptoms.


Submitted Aug. 28, 2002
Revised Dec. 18, 2002
Accepted Jan. 20, 2003

© 2003 Canadian Medical Association
Deficit syndrome and NO

involved in the plasticity of neurons. In animal experiments, there is some evidence that NO is involved in memory, behaviour and emotion.

As evidence supporting the relation between NO and central nervous system function continues to accumulate, evidence of a relation between NO and schizophrenia is also increasing. In 1993, Akbarian et al. reported a distorted distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase (NADPH-d) neurons in various areas of postmortem brains of people who had schizophrenia. Given that NADPH-d coexists with NOS, their discovery suggests that there may be an NO production abnormality in the brains of patients with schizophrenia. Karson et al. later showed that the NOS concentration is increased in the cerebellar vermis of postmortem brains of those who had schizophrenia. By means of ex vivo experiments, Das et al. showed NOS activity to be significantly elevated in the platelets of drug-naïve patients with schizophrenia compared with controls, drug-treated patients with schizophrenia and patients with panic disorder, and Herken et al. reported a remarkable increase in nitrite plus nitrate levels in red blood cells of patients with schizophrenia compared with control subjects. These findings suggest that there is excess NO production in the brains of individuals with schizophrenia. Excess NO is thought to be neurotoxic owing to the formation of peroxinitrite, a very reactive anion with protonation, which is formed from the reaction of NO with superoxide.

Strauss and colleagues proposed that positive and negative symptoms in schizophrenia be studied separately, and in 1980, Crow suggested that schizophrenia be divided into 2 types — Type I, which is characterized by positive symptoms, and Type II, which is characterized by negative symptoms and constant symptoms. Later, patients with Type II schizophrenia were reported to have decreased intelligence and enlarged cerebral ventricles, suggesting that neuron loss might underlie the pathogenesis of Type II schizophrenia. Carpenter and colleagues further classified negative symptoms into 2 types — primary negative symptoms, which are enduring, and secondary negative symptoms, which are more transient and occur secondary to other factors (e.g., adverse effects of neuroleptics, anxiety, suspiciousness, depression and motor retardation). They termed the subtype of schizophrenia that is characterized by primary negative symptoms “deficit syndrome” and established the criteria for its diagnosis. Similarly, Keefe et al. attempted to distinguish Kraepelinian from non-Kraepelinian schizophrenia on the basis of symptom outcome and degree of deterioration.

Given these lines of evidence, we hypothesized that excess NO production may lead to neurodegeneration and the formation of enduring negative symptoms in the brains of patients with the deficit form of schizophrenia. To support this working hypothesis, we investigated the levels of nitrate, a marker of in vivo NO production, in plasma from patients with deficit and non-deficit forms of schizophrenia and healthy controls.

Methods

This study was carried out in accordance with the latest version of the Declaration of Helsinki, and the design was approved by the Ethics Committee of the Department of Neuropsychiatry, Keio University. Informed consent was obtained from each patient upon provision of a thorough explanation of the procedures.

The subjects consisted of 25 outpatients (14 females) who met the DSM-IV criteria for schizophrenia on their first visit to our clinics and 12 (6 females) healthy volunteers (controls). Each patient was diagnosed using the Japanese version of the Schedule for the Deficit Syndrome (SDS) after at least 1 year of follow-up by an attending psychiatrist. Inter-rater and test–retest reliabilities of the differential diagnosis between the deficit and non-deficit forms of schizophrenia in our group were good (kappa = 0.86, and kappa = 0.93, respectively).

None of the patients had taken antipsychotics for at least 2 weeks before blood collection, but 6 patients had taken 1 or 2 types of benzodiazepine. Patients with conditions possibly affecting their plasma nitrite and nitrate levels, such as drug abuse and certain diseases (blood, neurological, hepatic, cardiovascular or renal), were excluded from this study. Moreover, none of the subjects had any history of these conditions.

Blood was collected between 1000 and 1200 hours. Plasma nitrite and nitrate concentrations were measured using a high-performance liquid chromatography (ENO-20, Eicom, Kyoto, Japan). The lower detection limit in our laboratory was 0.1 mmol/L.

Hepatic and renal functions and cell counts were determined at the time of blood sampling to confirm that these values were within normal limits. There were 2 athletes and 12 smokers among our subjects. In addition to a general analysis of all subject data, we also conducted an analysis excluding data from the patients
who took benzodiazepines, the smokers and the athletes. Exclusion of these subjects did not substantially change the overall findings.

Data are expressed as means (and standard error of the mean [SEM]) and were analyzed with 1-way analysis of variance (ANOVA). Post-hoc analysis was performed with Scheffé’s test.

Results

The mean age of deficit patients was 27.8 (SEM 1.4) years, non-deficit patients was 31.9 (SEM 1.5) years and controls was 32.7 (SEM 1.6) years. Mean plasma nitrite levels of deficit patients, non-deficit patients and controls were 4.64 (SEM 0.70) µmol/L, 4.87 (SEM 0.55) µmol/L and 4.61 (SEM 0.83) µmol/L, respectively ($F = 0.046, p = 0.95$). Mean plasma nitrate levels of deficit patients, non-deficit patients and controls were 28.0 (SEM 2.5) µmol/L, 44.2 (SEM 5.5) µmol/L and 36.8 (SEM 2.8) µmol/L, respectively (Fig. 1). Plasma nitrate levels of deficit patients were significantly lower than those of non-deficit patients ($F = 3.87, p = 0.03$).

Discussion

It is generally accepted that schizophrenia constitutes a wide spectrum of diseases. Among the many proposals to divide schizophrenia into subgroups, the deficit and non-deficit classification is one of the most heavily investigated. Previous investigations have revealed differences in intelligence, cognitive function, brain structure and brain function between the 2 forms of schizophrenia. The findings of this study (i.e., different plasma nitrate levels) may further support the heterogeneity between deficit and non-deficit forms of schizophrenia.

Contrary to our working hypothesis, data obtained in this study suggest NO production is diminished in patients with deficit syndrome compared with non-deficit syndrome patients. It remains unclear whether reduced NO production is related to the pathogenesis of deficit syndrome (negative symptoms), but interesting possibilities have been raised in the literature. We previously showed that symptoms of deficit syndrome do not respond to bromperidol, a dopamine D$_2$ receptor antagonist, whereas those of non-deficit syndrome do. Amphetamines and related substances, dopamine releaser and dopamine reuptake inhibitors induce only positive symptom-like conditions in animals and humans. These findings suggest that factors other than the central dopaminergic system underlie the pathogenesis of deficit syndrome.

On the other hand, the phencyclidine (PCP) model of schizophrenia mimics not only positive symptoms but also negative symptoms, suggesting N-methyl-D-aspartate (NMDA) receptors may be related to negative symptoms (because PCP is a NMDA receptor antagonist). The 3 subtypes of NOS are neuronal (NOS1), inducible (NOS2) and endothelial (NOS3). Production of neuronal NO is catalyzed by NOS1, is Ca$^{2+}$-dependent and is stimulated by activation of NMDA receptors that allow for the influx of Ca$^{2+}$. Moreover, PCP itself was shown to be a suicide inhibitor of NOS in the brain. Bird et al. showed PCP-induced behavioural effects and neuronal activity to be reduced in mice treated with NOS1 antisense oligonucleotides and in NOS1 knockout mice, suggesting the NO system in the brain to be necessary for PCP-induced effects. In addition, nitric oxide donors reportedly block PCP-induced behaviour, and inhibitors of NOS have been shown to potentiate PCP-induced behavioural effects and neuronal activity. These data suggest that reduction of NMDA receptor-mediated NOS activity might contribute to the pathogenesis of negative symptoms and that the NMDA receptor–NO system might be a target for novel drugs designed to treat the negative symptoms of schizophrenia.

This study is limited in that the source of diminished NO production could not be precisely localized. However, Srivastava et al. showed reduced nitrite levels in polymorphonuclear leukocytes, in which only NOS1 is
constitutively expressed, in patients with schizophrenia. Shinkai et al showed the NOS1 gene polymorphism to confer increased susceptibility to schizophrenia. These data suggest that NOS activity in the brain is attenuated in some forms of schizophrenia.

We found no significant difference in plasma nitrite or nitrate levels between patients with schizophrenia in general (deficit plus non-deficit) and controls. This is contrary to previous studies that suggest NO production is increased in brains of individuals with schizophrenia. However, most subjects in previous studies were taking antipsychotics; ours were drug naive. Given the finding that long-term treatment with antipsychotics induces NOS2 mRNA in various regions of the brain, there is a possibility that antipsychotic treatment increased NOS activity in the previous research subjects. However, Das et al showed increased NOS activity in the platelets of drug-free patients with schizophrenia, and later reported decreased plasma nitrate levels of drug-free patients with schizophrenia. Consistent with our results, Srivastava et al found no significant change in the plasma total nitrite and nitrate content between drug-free patients and controls. We speculate that the discrepancies reflect the heterogeneous psychotic condition of subjects.

Deficit syndrome is characterized by restricted affect, diminished emotional range, poverty of speech, curb- ing of interests, diminished sense of purpose and diminished social drive. Externally, these symptoms are similar to those of depression. However, since we have documented increased plasma nitrate levels in depressed patients compared with those not in a non-depressed state, we speculate that the amount of NO production may differ between deficit syndrome and depression.

In conclusion, plasma nitrate levels in patients with deficit-type schizophrenia were significantly lower than those in patients with non-deficit type. These results suggest there is a difference in NO synthesis in patients with deficit and non-deficit types of schizophrenia.

Acknowledgements: We thank Dr. Gobei Yagi and Dr. Masahiro Asai for their introduction of patients and useful discussions.

This study was supported by a Grant-in-Aid for Scientific Research (C) (No. 13671031) from the Japanese Ministry of Education, Culture, Sports, Science and Technology.

Competing interests: None declared for Dr. Nakamura. Dr. Suzuki has received speaker fees from Eisai Pharmaceutical Co. Dr. Nakaki has received speaker fees from Chugai Pharmaceutical Co. Dr. Miyaoaka has received speaker fees from Sankyo Pharmaceutical Co., Sumitomo Pharmaceutical Co. and Fujisawa Pharmaceutical Co.

References